- Trial Phase
- Phase 3
- Time to Market
- If Phase 3 data is positive (expected 2H 2026), an NDA submission would likely follow in 2027, with potential FDA approval in 2027-2028.
- Why 8/10
- The next hard, dated catalyst is the topline Phase 3 data readout from the pivotal FURVENT trial, expected in 2H 2026 (per the company's Q2 2026 earnings release on Aug 12, 2026). This is a make-or-break binary event for a pre-revenue single-asset biotech where firmonertinib drives essentially all of the company's valuation.
The pivotal Phase 3 FURVENT topline readout for firmonertinib, expected in 2H 2026 (likely within weeks), is the single most important catalyst for AVBP. With ~17.6% of shares short and 20+ days to cover, positive data could trigger a significant squeeze; negative data would be devastating for this pre-revenue single-asset biotech. Monitor for the data release and consider the binary risk/reward carefully.
Price Chart
Executive Summary
Firmonertinib is ArriVent BioPharma's (AVBP, Nasdaq) lead drug candidate — an oral EGFR inhibitor targeting exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company has completed enrollment in the pivotal Phase 3 FURVENT trial and expects topline data in 2H 2026. This is a make-or-break catalyst for a pre-revenue biotech with no approved products. Analyst sentiment is strongly bullish (17 Buy/Strong Buy, mean PT $44.70 vs ~$29 stock), but the binary risk is extreme — trial failure would be devastating. High short interest (~17.6% of outstanding, 20+ days to cover) adds squeeze potential on positive data but also reflects skepticism. The company has ~$326M cash (funding into Q4 2027) and an ATM facility for up to $250M in additional capital.
How It Works
Firmonertinib is an oral pill that blocks a specific type of mutated EGFR protein found in some lung cancers (exon 20 insertion mutations). EGFR is a protein on cell surfaces that can drive uncontrolled growth when mutated. By inhibiting this mutated EGFR, firmonertinib aims to stop cancer cells from growing and dividing. It is taken as a daily pill, unlike some competing treatments that require intravenous infusion.
Trial Status
Two Phase 3 trials are ongoing: FURVENT (pivotal, first-line EGFR exon 20 insertion NSCLC — enrollment completed, topline data expected 2H 2026) and ALPACCA (PACC mutant NSCLC — dosing initiated). Preclinical data was presented at AACR 2026.
The Two-Sided Case
Upcoming Catalysts
- Topline Phase 3 FURVENT data readout (expected 2H 2026, likely within weeks)
- Potential NDA submission if Phase 3 data is positive
- ARR-002 (MUC16/NaPi2b ADC) IND cleared May 2026; first patient dosing expected 2H 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ArriVent BioPharma, Inc. PRESS-RELEASE AVBP ·Originating report